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The majority of patients with terminal breast cancer show signs of bone metastasis,
the most common cause of pain in cancer. Clinically available drug treatment options
for the relief of cancer-associated bone pain are limited due to either inadequate pain
relief and/or dose-limiting side-effects. One of the major hurdles in understanding the
mechanism by which breast cancer causes pain after metastasis to the bones is the
lack of suitable preclinical models. Until the late twentieth century, all animal models
of cancer induced bone pain involved systemic injection of cancer cells into animals,
which caused severe deterioration of animal health due to widespread metastasis. In
this mini-review we have discussed details of a recently developed and highly efficient
preclinical model of breast cancer induced bone pain: Walker 256 cancer cell- induced
bone pain in rats. The model involves direct localized injection of cancer cells into a single
tibia in rats, which avoids widespread metastasis of cancer cells and hence animals
maintain good health throughout the experimental period. This model closely mimics the
human pathophysiology of breast cancer induced bone pain and has great potential to
aid in the process of drug discovery for treating this intractable pain condition.
Keywords: breast cancer, metastasis, bone pain, Walker 256 cell, rat model
INTRODUCTION
The most common cause of pain in cancer arises from bone metastasis, and around 73% of
patients with terminal breast cancer exhibit indications of bone metastases (Coleman, 2006;
Currie et al., 2013; Bu et al., 2014). Of these, 75% suffer severe bone pain and pathological
fractures (Ibrahim et al., 2013). This is in contrast to primary breast tumors in the tissue
of origin that cause very little or no pain at all (Lozano-Ondoua et al., 2013). Clinically,
nonsteroidal anti-inflammatory drugs are the mainstay of treatment, often in combination with
strong opioid analgesics, radiotherapy in the initial stages of metastasis, and adjuvant agents
that inhibit osteoclast activity such as bisphosphonates and denosumab (Mantyh et al., 2002;
Colvin and Fallon, 2008; Fallon et al., 2016; Fernandes et al., 2016). The principal challenge in
understanding the pathophysiological mechanisms of cancer-induced bone pain (CIBP) is the
development of an animal model which has characteristics in common with that of human
CIBP (Slosky et al., 2015). It is only recently that preclinical studies have begun to determine
how metastatic cancers may interact with the bone microenvironment resulting in pain
Abbreviations: CIBP, cancer- induced bone pain; ITI, intra-tibial injection.
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(Lozano-Ondoua et al., 2013). Until the late twentieth century, all
animal models of CIBP relied on systemic injection of carcinoma
cells, which resulted in poor animal health because of metastases
in vital organs such as the liver, lungs, brain, and multiple sites in
bone (Urch, 2004; Simmons et al., 2015). Subsequently, the more
efficient method of local infusion of cancer cells into a single bone
was developed, thereby avoiding systemic spread of cancer cells
and themaintenance of good general animal health (Schwei et al.,
1999). Although, multiple breast cancer cell lines have been used
to induce bone tumors in rats and mice, the focus of this mini-
review is confined to research in which Walker 256 rat breast
cancer cells have been used to induce bone pain in rats.
RAT AS THE SPECIES OF CHOICE
Rats and mice are the most commonly used animal species for
pain research (Walker et al., 1999), with rats being superior
to mice in many practical respects (Wilson and Mogil, 2001;
Mogil, 2009). The advantage of mouse pain models is the
availability of transgenic mice for dissecting pathophysiological
mechanisms (Mogil and Grisel, 1998) and mouse models of
breast cancer might recapitulate key aspects of human breast
cancer including poor immunogenicity and high metastatic
potential (Hahn et al., 2006). However, the main disadvantage of
mice is their small size, making direct injection of tumor cells
into the bone technically challenging (Pacharinsak and Beitz,
2008). By contrast, rat models are considered very suitable for
efficacy assessment of therapeutic interventions for the treatment
of breast CIBP (Medhurst et al., 2002). The model using Walker
256 cells can be induced in both sexes of rats (Liu et al., 2010,
2011) and different rat strains are compatible with these cells
(Earle, 1935; Jensen and Muntzing, 1970). Stage of the estrous
cycle in female rats does not alter the development of CIBP (Zhu
G. Q. et al., 2014).
SUITABILITY OF WALKER 256 CELLS
TheWalker tumor was first discovered in the breast of a pregnant
albino rat (Rattus norvegicus) in 1928 by Dr. George Walker
in Baltimore and it is regarded as a carcinosarcoma (McEuen
and Thomson, 1933; Simpkins et al., 1991). It is one of the
most widely used transplantable tumors in experimental research
(Justice, 1985; Brigatte et al., 2007; Fan et al., 2016; Gambeta et al.,
2016; Gao et al., 2016; Sroka et al., 2016; Wu M. et al., 2016).
Indeed, these cells are one of the most preferred cell lines because
of the ease with which they can be standardized, maintained and
propagated in vitro, as well as their extensive use in vivo since
1937 (Michaelson and Orcutt, 1957; Brigatte et al., 2016; Galuppo
et al., 2016; Pigatto et al., 2016; Trashkov et al., 2016; Yalovenko
et al., 2016).
Walker 256 cells cause significant bone resorption and
increase skeletal fragility at the site of implantation in rats (Kurth
et al., 2000), consistent with the phenotype observed in breast
cancer patients with bone metastasis (Shih et al., 2004). In
addition to being a reproducible method for inducing skeletal
metastasis (Blouin et al., 2005; Mao-Ying et al., 2006; Badraoui
et al., 2009), this model mimics key features of human breast
CIBP, including pharmacological profile (Mao-Ying et al., 2006,
2012; Cao et al., 2010). Walker 256 cells can be used in a variety
of rat strains (Hang et al., 2015; Lu et al., 2015) because these
cells produce uniformly rapid growth, show very little regression,
and are readily adaptable (Lewis et al., 2013; Oliveira and Gomes-
Marcondes, 2016).
Growth of Walker 256 cells in the form of tumor is practically
independent of the age and weight of the animals at the time
of their inoculation (Walpole, 1951). Another advantage is that
after unilateral intra-tibial injection (ITI), tumor cells do not
metastasize to the contralateral tibia during the experimental
period and they only cause structural degradation of bones in the
ipsilateral limb but not the contralateral limb (Kurth et al., 2001,
2002). They also generally do not metastasize to highly perfused
organs such as the lungs (Brigatte et al., 2007), in contrast to
other cell lines such as the 13762 rat mammary carcinoma cell
line or the c-SST2 rat mammary carcinoma cell line, which
spontaneously metastasize (Blouin et al., 2005).
Although, many scientists tend to presume that tumor cell
lines behave indefinitely in a uniformmanner (Lewis et al., 2013),
changes may be induced by factors such as extended in vitro
growth time, high passage number and cross contamination
with other cell lines (Sacchi et al., 1984; Chang-Liu and
Woloschak, 1997; Buehring et al., 2004; Liscovitch and Ravid,
2007). Immortalized cancer cell lines may also evolve in vivo over
time in the animal models in which cancer is induced (Poste
et al., 1982b). Various heterogeneous subpopulations of tumor
cells within a tumor mass possess diverse metastatic potential
and different propensities formetastasis to various organs (Fidler,
1978; Poste et al., 1982a). Similarly, immortalized Walker 256
cancer cell lines from different cell banks may possess diverse
characteristics and behavior in vivo despite the fact that these
cell lines are from rat origin and are without contamination
(Lewis et al., 2013). In general, cell lines may be authenticated
by short tandem repeat (STR) profiling of the microsatellite
regions of DNA (Nims et al., 2010). However, as there is no
reference DNA profile of the Walker 256 cell line (Lewis et al.,
2013), researchers typically procure cells of a defined passage
number from reputable cell banks. To minimize within- and
between- laboratory variability in the use of these cells in vivo,
it is important that cultured cells are banked and frozen at early
passages, and that culture conditions including growth media,
temperature, humidity and exposure to drugs are standardized
(Marx, 2014).
GENERAL METHODOLOGY
Although there are minor between-laboratory variations, the
general method for induction of breast CIBP in rats has several
aspects in common. The procedure generally involves making
an incision to the skin and muscle around the knee joint of
the anesthetized rat and injecting cancer cells into the tibial
bone, followed by sealing of the drilled hole with bone wax,
suturing of the wound and close monitoring of animals during
post-surgical recovery (Mao-Ying et al., 2006). Cells can also be
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injected in the femur (Gui et al., 2013, 2015). Small differences
in the number of injected Walker 256 cancer cells due to
experimental errors typically have a minimal effect on the study
outcome (Kurth et al., 2001). The physical process for injection
of Walker 256 cells into the medullary canal of the bone does not
impact the study outcome adversely as emphasized by the normal
fibroblastic healing response around the drilled hole of injected
bone (Kurth et al., 2002;Mao-Ying et al., 2006). Although outflow
of cells during the injection process can be a common occurrence
associated with the model, the syringe can be left in place inside
the medullary canal of the bone for an additional 1 or 2min to
avoid leakage of cells along the injection track (Mao-Ying et al.,
2006; Yu et al., 2009; Miao et al., 2010; Dong et al., 2011; Hu S.
et al., 2012).
TIME FRAME FOR DEVELOPMENT OF
PAIN BEHAVIORS AND ANALGESIC
EFFICACY TESTING
One of the most important and critical factors in the study
of pain behavior and extent of bone destruction in this model
is the timing of observations post-surgery (Qiu et al., 2012).
Large tumors can develop in just a few days (Justice, 1985).
However, the time period for development of pain behaviors
may vary between studies based upon factors such as cell
invasiveness and sex of the experimental animals (Wang et al.,
2011). Pain behavior due to the surgical process may be evoked
in the ipsilateral (injected) hind paws if the animals are tested
immediately after the inoculation surgery (Lan et al., 2010; Dong
et al., 2011). Hence a recovery period of 2–3 days post-surgery
must be provided for the animals (Wang et al., 2011). For the
purposes of studying different mechanisms of breast CIBP and
for efficacy profiling of molecules with potential to be developed
as novel analgesic agents, it is best to avoid extending the model
beyond 20–25 days post-surgery (Mao-Ying et al., 2006; Yu et al.,
2009; Cao et al., 2010; Tong et al., 2010; Hang et al., 2014)
due to overall poor animal health and ethical concerns (Kurth
et al., 2001). In particular, prolonged observation times may
be associated with more complex pathophysiology arising from
systemic metastasis due to severe osteolysis (Qiu et al., 2012).
Hence, the period between days 6 and 18 post-ITI is typically
chosen for investigation of breast CIBP mechanisms and the
efficacy testing of novel compounds with potential as analgesic
agents (Wang et al., 2011; Hu et al., 2012a; Wang L. N. et al.,
2012b).
NATURE OF PAIN MANIFESTATION
In Walker 256 cell-CIBP, up-regulated expression and release of
pro-inflammatorymediators including prostaglandin E2 (PGE2),
nerve growth factor (NGF), and proinflammatory cytokines
including interleukin (IL)-1β, IL-6 and tumor necrosis factor-α
(TNF-α) in the spinal cord and dorsal root ganglia contributes to
the pathogenesis of bone pain in rats (Cao et al., 2010; Lan et al.,
2010; Liu et al., 2010; Dong et al., 2011; Mao-Ying et al., 2012;
Yao et al., 2016; Zhu et al., 2016). Hence, neuroinflammation is
an important pathogenic characteristic of this model (Hu S. et al.,
2012; Song et al., 2015).
Similar to the clinical situation, Walker 256 cell-CIBP
manifests as spontaneous pain, hyperalgesia, allodynia as well
as ambulatory pain, the severity of which largely depends upon
the number of inoculated cells, but can also be affected by
other experimental factors including cell origin as well as strain
or sex of the animals used (Mao-Ying et al., 2006; Liu et al.,
2010). Similarly, hind paw hypersensitivity induced by ITI with
Walker 256 cells may be either unilateral (Liu et al., 2010; Tong
et al., 2010; Dong et al., 2011; Wang J. et al., 2012; Wang L.
N. et al., 2012b) or bilateral (Mao-Ying et al., 2006, 2012; Zhao
et al., 2013; Li et al., 2014). Peripheral mechanisms including
circulating factors and transmedian sprouting, or central
mechanisms such as signaling via commissural interneurons in
the spinal cord and brain stem may underpin unilateral injury-
induced contralateral mirror effects (Koltzenburg et al., 1999).
This mirror image effect may also be correlated with spinal
glia cell activation, proinflammatory cytokine production, and
morphological changes within the local nerve, suggesting the
involvement of glia (Chacur et al., 2001). The mirror image pain
behavior induced in the contralateral hind paw in this model may
be observed when the tumors are in the advanced stage (Miao
et al., 2010; Zhao et al., 2013; Li et al., 2014) Typically though,
contralateral pain behaviors are of reduced intensity compared
with the ipsilateral hind paw (Miao et al., 2010).
Thermal and mechanical pain behaviors are underpinned by
different mechanisms (Paqueron et al., 2003;Wang J. et al., 2012).
Cutaneous nociceptors are particularly sensitized by thermal
stimuli and nociceptors present in deep somatic tissues such as
joints andmuscle exhibit pronounced sensitization tomechanical
stimuli (Schaible, 2007). Although, thermal hyperalgesia has
been reported in this model (Liu et al., 2011; Duan et al.,
2012; Wang J. et al., 2012), there are several studies in which
hindpaw hypersensitivity to an applied noxious heat stimulus is
not observed in rats following a unilateral ITI of Walker 256 cells
(Mao-Ying et al., 2006, 2012; Yao et al., 2008; Miao et al., 2010;
Wang et al., 2011). Again, these differences may be attributed
to various factors including between-vendor differences in
animals and cancer cell-related factors. For this reason, thermal
hyperalgesia is not typically used as a pain behavioral endpoint
in this model (Yu et al., 2009; Cao et al., 2010; Tong et al., 2010;
Zhao et al., 2010; Dong et al., 2011). A between-study comparison
of Walker 256 cell- CIBP rat model is presented in Table 1.
REGRESSION OF TUMOR AND
RESOLUTION OF PAIN
Similar to the well-known human scenario of breast cancer
regression (Lewison, 1976; Hutter, 1982; Burnside et al., 2006;
Barry, 2009; Onuigbo, 2012), Walker 256 breast cancer cells
may also potentially transform into a regressive variant in vivo
(Guimarães et al., 2010) resulting in complete regression if
the study is prolonged (Jensen and Muntzing, 1970; Cavalcanti
et al., 2003; Schanoski et al., 2004). The mechanisms underlying
spontaneous regression are not entirely clear but may involve
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TABLE 1 | Comparative summary of previous work by others using the Walker 256 cell-CIBP model in rats.
Number of Rat Sex, Strain- Time frame of Nature of pain References
cells (Number of hind paw hypersensitivity behavioral responses
injected studies) post- ITI (Days) in the hind paw
MA MH TH S/MEP
4× 103 F, W- (1) 14–19 + NA NA + Cao et al., 2010
5× 103 F, SD- (1) 6–14 + NA NA NA Zhao et al., 2013
1× 104 F, W- (1) 9–21 + NA NA + Ke et al., 2013
1× 104 F, SD- (1) 7–18 + NA + + Yao et al., 2016
3× 104 F, SD- (1) Tested day 10 + NA NA NA Liu et al., 2012
4× 104 F, W- (3) 3–16 + NA NA NA Dong et al., 2011; Bu et al., 2014; Xia et al.,
2014; Ye et al., 2014; Guan et al., 2015
F, SD- (2)
5× 104 F, SD- (2) 7–18 + NA + NA Qiu et al., 2014; Wang et al., 2016
5× 104 F, SD- (1) 5–14 NA + + NA Qiu et al., 2012
1× 105 F, W- (2) 12–24 + NA + + Bao et al., 2014b, 2015c
1× 105 M&F, SD- (4) 5–28 + NA + NA Liu et al., 2011; Jiang et al., 2014; Bao et al.,
2015a; Fan et al., 2015; Jiang et al., 2015; Ren
et al., 2015; Jiang et al., 2016
M&F, W- (3)
1× 105 F, SD- (8) 6–21 + NA NA + Lan et al., 2010; Liu et al., 2010; Chen et al.,
2012; Hang et al., 2012; Wang L. N. et al.,
2012a,b; Jin et al., 2014; Bian et al., 2016
1× 105 F, SD- (8) 5–21 + NA NA NA Wang et al., 2011; Hu et al., 2012a,b; Hang
et al., 2013b,c; Hu et al., 2013; Hang et al.,
2015, 2016; Zhu et al., 2015
F, W- (1)
1× 105 F, SD- (1) 6–15 NA + NA + Hang et al., 2014
1× 105 F, SD- (1) 6–15 NA + NA NA Hang et al., 2013a
1× 105 F, W- (1) Tested day 14 NA NA NA + Bao et al., 2015b
2× 105 F, SD- (2) 3–21 + NA NA NA Huang et al., 2014; Jin et al., 2015; Pan R.
et al., 2015; Wu J. X. et al., 2016
F, W- (1)
2× 105 F, W- (1) 7–21 NA + − + Miao et al., 2010
2× 105 F, SD- (1) 7–25 NA + − NA Li et al., 2014
2× 105 F, W- (1) 7–21 NA + + + Wu et al., 2012
3.5× 105 F, SD- (2) 5–21 + NA + NA Wang J. et al., 2012; Wang et al., 2015
4× 105 F, SD- (1) 5–21 + NA − + Yin et al., 2010
4× 105 F, SD- (1) 4–32 + NA − NA Huang et al., 2012; Mao-Ying et al., 2012
F, W- (1)
4× 105 F, W- (2) 7–21 + NA + + Duan et al., 2012; Yang et al., 2015; Zhou
et al., 2015
F, SD- (1)
4× 105 SD- (1) 3–21 + NA NA + Cheng et al., 2014
4× 105 M&F, W- (10) 3–21 + NA NA NA Yu et al., 2009; Tong et al., 2010; Hu S. et al.,
2012; Wang X. W. et al., 2012a,b; Li et al.,
2013; Zhang et al., 2013; Gong et al., 2014;
Zhu B. et al., 2014; Hu S. et al., 2015; Li et al.,
2016; Song et al., 2016
F, SD- (2)
4× 105 F, W- (1) 6–20 NA NA + NA Xu et al., 2013
5× 105 F, SD- (1) 7–21 + NA + + Liu et al., 2013
(Continued)
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TABLE 1 | Continued
Number of Rat Sex, Strain- Time frame of Nature of pain References
cells (Number of hind paw hypersensitivity behavioral responses
injected studies) post- ITI (Days) in the hind paw
MA MH TH S/MEP
5× 105 F, SD- (5) 5–21 + NA + NA Bao et al., 2014a; Liu et al., 2014; Shen et al.,
2014; Hu X. M. et al., 2015; Zhang et al., 2015;
Zhu et al., 2016
F, W- (1)
5× 105 F, SD- (1) 7–10 + NA NA + Lu et al., 2015
5× 105 F, SD- (3) 9–21 + NA NA NA Chen et al., 2013, 2015; Song et al., 2015
5× 105 F, SD- (1) 7–10 NA + NA + Lu et al., 2016
5× 105 M, SD- (1) 5–14 NA + NA NA Xu et al., 2015
1× 108 F, SD- (1) 7–25 + NA NA NA Zhao et al., 2010
+, observed;−, not observed; F, female; M, male; MA, mechanical allodynia; MH, mechanical hyperalgesia; NA, not assessed; SD, Sprague Dawley; S/MEP, spontaneous or movement-
evoked pain; TH, thermal hyperalgesia; W, Wistar.
development of an adaptive immune response (Pardoll and
Topalian, 1998; Rees and Mian, 1999), differential propagation
of tumor sub clones in their microenvironment (Khong and
Restifo, 2002) and consequent elimination by immune cells,
antibodies, cytokines, and chemokines (Dunn et al., 2002, 2006;
Bui and Schreiber, 2007; Jaganjac et al., 2008). Physical activity
of the animals, exercise (Hoffman et al., 1962; Deminice et al.,
2016b), dietary factors (Bekesi and Winzler, 1970; Kwong et al.,
1984; Luty et al., 2016), or hormonal levels (Khegai, 2013;
Khegay and Ivanova, 2015) may influence the regression of these
cells or inhibit the activities driven by these cells (Campos-
Ferraz et al., 2016; Cruz et al., 2016; Deminice et al., 2016a;
Fracaro et al., 2016; Toneto et al., 2016). In most studies, tumor
regression is generally overlooked as the tumor-bearing rats
are sacrificed before regression is evident (Guimarães et al.,
2010). Thus, the verification of tibial tumor burden post-mortem
is very important. However, the beginning of pain behavior
resolution at 20–25 days post-surgery is typically not due to
tumor regression, but may involve neuro-immune mechanisms
(Zhao et al., 2010; Xu et al., 2013; Huang et al., 2014). In previous
work by others using different cancer cell lines, up regulation
of the endogenous opioid system is implicated in spontaneous
pain behavior resolution (Muralidharan et al., 2013). Similarly,
endogenous opioid system could also have a role in Walker
256 cell-CIBP model (Li et al., 2016). In addition, lipoxins and
endogenous lipoxygenase-derived eicosanoids, which represent a
unique class of lipid mediators, have a broad spectrum of anti-
inflammatory and antinociceptive activities. These are known
to suppress the expression of spinal pro-inflammatory cytokines
and might also contribute to spontaneous resolution of Walker
256 cell-CIBP in rats (Hu S. et al., 2012). Inflammation, which
is an important component of cancer pain (Falk and Dickenson,
2014) mostly involves active endogenous processes targeted
at protecting the host, and is generally self-limiting and self-
resolving (Chiang et al., 2005; Serhan and Savill, 2005; Schwab
and Serhan, 2006).
TARGETS FOR NOVEL ANALGESIC DRUG
DISCOVERY
The pathobiology of Walker 256 cell-CIBP in rats is complex
involving inflammatory, neuropathic and tumorigenic
components (Cao et al., 2010). Following injection, these
cells cause osteolysis and bone resorption (Kurth et al., 2000,
2001; Yu et al., 2009) and increase oxidative stress and impair
the antioxidant system in the bone microenvironment (Badraoui
et al., 2009). They cause enhanced synthesis of IL-1β and
TNF-α at the mRNA or protein level along with nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB),
which indicates that increased neuroimmune responses is one
of the important factors responsible for pain in this model
(Cao et al., 2010; Song et al., 2016). Injection of these cells
in the bones sequentially activates the extracellular signal-
regulated protein kinase (ERK)/mitogen-activated protein
kinase (MAPK) pathway in various cell types in the spinal
cord of rats (Wang et al., 2011; Wang X. W. et al., 2012b;
Bian et al., 2016). Sodium channels expressed by sensory
nerve fibers including voltage gated sodium ion channels
(Nav)1.7, Nav1.8, and Nav1.9 (Miao et al., 2010; Qiu et al.,
2012; Pan J. et al., 2015) as well as potassium ion channels,
high-voltage-activated calcium channels, hyperpolarization-
activated cation channels, transient receptor potential cation
channel subfamily V member 1 (TRPV1) (Duan et al., 2012;
Xu et al., 2013; Xia et al., 2014), and acid-sensing ion channel
3 (Qiu et al., 2014) may also be important determinants of
enhanced neuronal excitability in this breast CIBP model
in rats.
Pain behavior and its relief in Walker 256 cell-CIBP in
rats is mediated by the endogenous effectors of several targets
interacting with their cognate receptors as summarized in
Table 2. These include important targets like opioid receptors,
toll like receptors, chemokine receptors, and purinergic
receptors.
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Toll like receptor 4 (TLR4) Lipopolysaccharide (Saitoh
et al., 2004)










Lan et al., 2010; Liu et al.,
2010; Mao-Ying et al.,
2012; Li et al., 2013; Liu




Lysophosphatidic acid Phospholipase C, MAPK,
protein kinase B (Akt) (Yung
et al., 2014), Ras homolog























Neuregulin 1 (NRG1) Akt-1, p38MAPK ErbB2 inhibitor Jiang et al., 2014
CX3C chemokine receptor 1
(CX3CR1)
Fractalkine p38MAPK Anti-CX3CR1 antibody Yin et al., 2010; Hu et al.,













Hu et al., 2012b, 2013; Jin
et al., 2015; Ren et al., 2015
Chemokine (C-X-C motif)
receptor CXCR3
CXCL9, CXCL10, CXCL11 Phosphoinositide -3 kinase
(PI3K), MAPK, Akt, ERK 1/2




Bu et al., 2014; Guan et al.,
2015
CXC motif receptor 4
(CXCR4)


















Chen et al., 2012
Purinergic P2X3 receptor
(P2X3R)
Extracellular ATP ERK (Seino et al., 2006) P2X3 receptor antagonist-
A-317491











(Arulkumaran et al., 2011)
inhibitor of P2X7R- Brilliant
Blue G (BBG); RNA
interference targeting the
P2X7R
Huang et al., 2014; Yang
et al., 2015
a3 glycine receptors Glycine Chloride current modulation
(Avila et al., 2013)
siRNA targeting a3 GlyR,
glycine receptor antagonist-
strychnine
Zhang et al., 2013
Adenosine A1 receptor Adenosine Protein kinase C (PKC)
(Hughes et al., 2015)
Adenosine A1 receptor
antagonist- DPCPX







Bao et al., 2014a, 2015b
(Continued)
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Thrombin Vascular endothelial growth
factor (VEGF), endostatin
(Ma et al., 2005)







protein kinase A (PKA)
GLP-1R agonists
GLP-1(7–36)




(Basu et al., 2011)
IL-1β, IL-6, IL-18, TNF-α CB2-selective antagonist-
AM630; CB2-selective
agonist- JWH-015
Lu et al., 2015, 2016
Prokineticin receptor 2
(PKR2)





PKA, NF-κB, ERK 1/2
(Taché and Million, 2015)
CRF receptor antagonist
(α-helical-CRF)
Fan et al., 2015







Chen et al., 2015; Jiang
et al., 2016; Yao et al., 2016
Sigma-1 Receptor Tryptaminergic trace




(Fontanilla et al., 2009)
Inositol trisphosphate (IP3) Sigma-1 receptor
antagonist -BD1047






PKA, MAPK (Zhao et al.,
2016)
None Wang L. N. et al., 2012a
LIMITATIONS AND POTENTIAL
IMPROVEMENT OF THE MODEL
Like many other preclinical models, this model has short-
comings which might hinder translation of promising preclinical
data into successful clinical outcomes. Mostly, efficacy profiling
in preclinical pain models is driven by a desire to reduce the
intensity of pain behavioral readouts. However, a reduction
in pain intensity is not always a good measure of the
success of a pain treatment (Ballantyne and Sullivan, 2015).
Pain is a subjective emotional experience and clinically, a
powerful analgesic response can be elicited by placebo treatment
(Kaptchuk andMiller, 2015; Tuttle et al., 2015). Hence, responses
in experimental animals may not necessarily correlate with the
responses expected from humans in the clinical setting. It is
also necessary to remember that animals at different ages may
process nociception differently (McKelvey et al., 2015) and hence,
selection of the correct age of animals that suits the experimental
goals may be critical.
Important factors that significantly affect pain research
outcomes, such as the sex of the researchers interacting with
the animals (Sorge et al., 2014) should not be overlooked in
preclinical studies. Sex of the experimental animals or human
subjects is a key source of variation in pro-nociceptive signaling
(Wiesenfeld-Hallin, 2005; Sorge et al., 2015). In a recent large-
scale gene regulatory study (Qu et al., 2015), the main findings
were that men and women may require different strategies for
treatment of pain, and so sex differences in pain research should
not be ignored (Murphy et al., 2009; Vacca et al., 2014, 2016;
Brings and Zylka, 2015; Cahill and Aswad, 2015; Ferrarelli, 2015).
There are many types of breast cancer in the clinical
setting (Sharma et al., 2010) with the potential to cause
pain, and the extent to which this model provides insights
into these various subtypes is currently unclear. It is also
important to have standardized protocols when using such
preclinical models in order to minimize between-investigator
and between-laboratory differences in implementation
(Freedman and Gibson, 2015).
CONCLUSION
Cancer-associated pain, especially intractable bone pain, is very
debilitating (Kane et al., 2015). Although, this model involving
ITI of Walker 256 cells in rats might not exactly mimic the
metastatic spread of breast cancer to the axial skeleton in humans
(Kurth et al., 2001, 2002), it provides great insights into the
pathobiology and mechanisms of breast CIBP and is hence used
very widely in experimental research (Du et al., 2015; Hang
et al., 2015; Hu S. et al., 2015; Liu et al., 2015; Lu et al., 2015).
Undoubtedly, it is one of the most suitable preclinical models
for efficacy assessment of novel compounds from discovery
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programs aimed at identifying drugs with potential to alleviate
breast CIBP in humans.
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